Milk Thistle: Silymarin, Liver Evidence and Label Checks

What is milk thistle?

Milk thistle (Silybum marianum) seeds contain silymarin, a mixture of plant compounds that includes silybin. A standardized extract tells you how much silymarin it contains. A seed-powder, ratio-extract, or phytosome label may give only the weight of the whole material, which is not the same number.

Milk thistle is marketed for “liver detox,” fatty liver, hepatitis, and hangovers. Research has tested specific extracts for liver disease and blood-sugar control; the preparation and condition matter when interpreting the results.

The historical liver use and the modern clinical test

Milk thistle’s liver reputation predates standardized extracts. In the 1850 edition of Culpeper’s Complete Herbal, the entry for Our Lady’s Thistle^[1] connects it with jaundice and what the period described as obstructions of the liver and spleen. The preparations include seed and distilled water, as well as external application near the liver. Those are quite different preparations from the oral extract capsules used in modern trials.

The white markings on the leaves also acquired a religious explanation. Museum West Zealand’s account of the Sorø apothecary garden^[2] recounts the legend that they came from the Virgin Mary’s milk, alongside folk use to promote milk production. This is an account of belief and use. Safety and effectiveness during breastfeeding remain uncertain.

The European Medicines Agency’s herbal summary^[3] still distinguishes traditional use from demonstrated treatment effects. It describes milk-thistle fruit preparations for digestive complaints such as fullness and indigestion and to support liver function after serious conditions have been excluded. That classification rests on longstanding use where clinical-trial evidence is insufficient.

Modern studies ask narrower questions: whether a specified extract changes liver enzymes, biopsy findings, blood sugar or survival. Those results need to be read alongside the preparation and condition tested.

What people take milk thistle for

NASH, or non-alcoholic steatohepatitis, is a form of fatty-liver inflammation. No benefit has been established for a healthy person, and there is no evidence-based dose for “detox.”

When to ask a doctor before taking milk thistle

• You have liver disease. Hepatitis, fatty liver, and cirrhosis need medical assessment and treatment. The US trials discussed here tested hepatitis C and non-cirrhotic NASH; they do not answer whether milk thistle helps cirrhosis.
• You take diabetes medicine. Milk thistle may lower blood sugar.
• You take prescription medicine. Milk-thistle interaction evidence is incomplete; ask a pharmacist about the specific combination.
• You are allergic to ragweed, chrysanthemums, marigolds, or daisies. Milk thistle belongs to the same plant family and may cause allergic reactions.
• You are pregnant or breastfeeding. Little is known about safety in these periods.

Common dosage

There is no recognized recommended daily amount or upper limit for milk thistle or silymarin.

A common label suggests a 140 mg silymarin capsule one to three times daily, totaling 140–420 mg. That is a third or less of the lowest US trial exposure: 420 mg three times daily equals 1,260 mg, and 700 mg three times daily equals 2,100 mg. The higher trial amounts have not been established as doses to copy.

The US trials split the daily amount into three doses. No trial cited here shows that taking it with food or at a particular time changes the result.

Extracts and dosages you can actually buy

Shelves carry standardized seed extracts, silybin phytosomes, unstandardized powders, ratio extracts, and tea. Only a label that states silymarin directly can be compared cleanly with the US trial amounts.

Standardized seed extract (80 percent silymarin)

A standardized seed extract states its silymarin percentage as well as its weight. The percentage lets you calculate the silymarin amount, as shown in the label section below.

Silybin phytosome

A phytosome combines silybin with phospholipids, such as phosphatidylcholine, to change how it is absorbed. The complex has its own weight, separate from the amount of silybin inside it. Labels often give only that larger number. Sample label line: "Milk Thistle Phytosome 300 mg."

There is human evidence that a particular complex can raise silybin exposure. In a small 1990 study^[4], nine healthy volunteers received a silybin–phosphatidylcholine complex or ordinary silymarin at the same 360 mg silybin amount; blood levels of silybin were higher after the complex. That was a single-dose absorption comparison, not a test of recovery from liver disease.

These absorption data do not establish equivalent treatment doses for standard extracts and phytosomes.

A 12-month fatty-liver trial^[5] tested silybin–phosphatidylcholine plus vitamin E against placebo. It treated 179 people and analyzed 138 who followed the protocol. That design cannot tell us whether the complex works better than a standard silymarin extract, or isolate silybin from the added vitamin E. There is no basis in these comparisons for assigning standard extract to “maintenance” and phytosome to “acute recovery.”

Ratio extracts, seed powder, and tea

Products described as "4:1" or "equivalent to 1,000 mg," seed powders, and teas give plant weight, not silymarin. Their silymarin content is unknown. Sample label line: "Milk Thistle Seed Extract 250 mg (4:1)."

All extracts at a glance

What to pay attention to on the label

Find milligrams of silymarin. If a label gives only extract weight and a percentage, multiply them: 175 mg of extract at 80 percent contains 140 mg of silymarin.

Which number on the label is the amount?

A capsule supplying 140 mg of silymarin, taken three times a day, provides 420 mg daily. The US trials used 420 mg or more per dose, three times a day. Another product lists 620 mg of extract at 80 percent per two capsules, taken once a day: about 496 mg of silymarin a day.

Misleading labels

Front milligrams vs the milligrams that count

One product lists 250 mg of a "4:1" seed extract, "equivalent to 1,000 mg" of milk thistle, with no silymarin percentage. The 1,000 mg describes the plant material used to make it, not silymarin, so you cannot tell how much silymarin you get. One seed powder lists 3 g per scoop, also with no silymarin amount.

“Standardized” describes a measured share of silymarin. “Supports liver health” or “liver detox” is a claim about what the product does; the percentage alone does not establish it. A “healthy blood sugar” claim points to a separate, limited body of diabetes research.

Phytosome products without a silybin amount

The 300 mg phytosome example above does not disclose its silybin content. A “better absorbed” claim should identify the tested preparation and the amount of silybin; the whole complex weight cannot supply that comparison.

Labels that may not match the bottle

Some milk thistle products have been found to contain silymarin amounts substantially different from their labels, or to be contaminated with pesticides, microbes, or mold toxins. The label alone cannot confirm the actual ingredient amount or rule out contamination.

Confusing servings and items per serving

If a bottle says 180 capsules but defines a serving as 3 capsules, it contains 60 servings. The Supplement Facts amount applies to all three capsules together.

A “clinically studied” claim also needs the study serving. The US trials used Legalon with 140 mg silymarin per capsule, taking three or five capsules three times daily. One capsule a day does not match either regimen.

Common Myths about Milk thistle

Does milk thistle detox or repair the liver?

“Detox” is not a defined clinical outcome, and the cited trials did not test hangovers. The liver studies below measured outcomes such as enzymes, biopsy changes and survival.

Drawbacks and side effects

In the US fatty-liver trial, adverse-event rates were not clearly different from placebo, but two treatment-related dose interruptions occurred in the 420 mg group.

The science behind milk thistle

Why silymarin is studied

Silymarin is a mixture of related flavonolignans, including silybin. Laboratory work has prompted interest in antioxidant, inflammatory and scarring pathways in liver disease. Those mechanisms are hypotheses about how an extract might act; they do not show that swallowed silymarin blocks alcohol or acetaminophen injury, regenerates human liver tissue, or treats a particular liver disease. Human trials have to measure the relevant outcome.

Hepatitis C

The 2012 trial enrolled 154 people with chronic hepatitis C whose earlier interferon treatment had failed. At four US centers, they took 420 or 700 mg of silymarin or placebo three times a day for 24 weeks. Only two people in each group met the main liver-enzyme target; the trial did not establish a benefit for that regimen. Virus-level differences were also not statistically clear.

Fatty liver (NASH)

The 2019 trial gave 78 people diagnosed with NASH but not cirrhosis the same doses or placebo for 48 weeks. Improvement on repeat biopsy occurred in 12 to 19 percent of each group, without a clear statistical difference. Liver scarring, called fibrosis, improved most with placebo, although the difference was statistically uncertain. On central pathology review, 49 participants (63 percent) failed or could not be assessed against the trial's tissue criteria; 14 of those 49 biopsies were unavailable or could not be evaluated. The authors therefore considered the result inconclusive.

Other results complicate a blanket negative verdict. In a 2017 trial of 99 people with biopsy-confirmed NASH^[7], 700 mg silymarin three times daily for 48 weeks did not meet its main target of reducing the disease-activity score, but more people in the silymarin group had an improvement in fibrosis on biopsy (22.4% versus 6.0% with placebo). A 2024 review of 26 trials^[8] reported favorable average ALT and AST changes across varied fatty-liver studies. Enzyme changes and a secondary fibrosis signal are worth investigating, but they do not establish that any retail extract prevents cirrhosis or repairs an injured liver.

Cirrhosis: a positive trial and a conflicting result

The US hepatitis-C and fatty-liver trials above do not settle cirrhosis. An older randomized trial in 170 people with cirrhosis^[9] compared 140 mg silymarin three times daily with placebo. It reported four-year survival of 58 percent versus 39 percent, each with a reported standard error of ±9 percentage points, a measure of uncertainty around the estimated survival rate. Average observation lasted 41 months. The study withdrew people who were noncompliant or missed follow-up, which complicates interpretation of the survival result.

A later multicenter trial in 200 people with alcohol-related cirrhosis^[10] tested 150 mg three times daily. Survival was similar: 15 of 103 assigned silymarin and 14 of 97 assigned placebo died during the trial. Only 125 completed the two-year study period. These conflicting results do not establish a dependable survival benefit, and they should not be collapsed into either “all liver trials failed” or “milk thistle treats cirrhosis.”

Blood sugar

A four-month trial in 51 people with type 2 diabetes^[11] tested 200 mg silymarin three times daily—600 mg a day—alongside conventional treatment. Twenty-five received silymarin and 26 received placebo. The published abstract reports improvements in fasting glucose, HbA1c, total cholesterol, LDL and triglycerides compared with placebo, but does not give the size or uncertainty of those differences.

HbA1c reflects average blood sugar over roughly three months. The 2018 review of seven small trials found a similar blood-sugar signal. It summarizes component studies rather than adding another independent group of patients. Most trials came from one region, and the evidence does not establish prevention of diabetes complications or an optimal supplement dose.

The signal is not uniform: a 2024 placebo-controlled trial^[12] reported no clear difference in fasting glucose, HbA1c or lipid markers after 12 weeks of 420 mg/day. Taken together, the results make blood-sugar effects a question for larger trials, not a reason to adjust diabetes medicine around a supplement.

Human antioxidant measurements

One 45-day trial in 40 adults with type 2 diabetes^[13] used 140 mg silymarin three times daily—420 mg a day. All participants completed the study. Compared with placebo, it increased the activity of two antioxidant enzymes, superoxide dismutase and glutathione peroxidase, and increased total antioxidant capacity in blood samples. A marker of inflammation, high-sensitivity CRP, also fell.

Measuring glutathione peroxidase activity is different from showing that glutathione itself increased in the liver. These blood measurements help explain why researchers are interested in silymarin, but they do not establish that a supplement regenerates liver tissue or protects someone from alcohol, acetaminophen or heavy-metal injury.

What is still open

The main uncertainties are clinical: which preparation, if any, produces a reliable benefit for a particular liver condition; whether the blood-sugar findings hold in larger, more varied populations; and whether increased silybin exposure translates into better outcomes. The available form comparisons do not establish a standard-to-phytosome dose conversion.

Liver tests and silymarin

Liver tests such as alanine aminotransferase (ALT), a liver enzyme measured in blood, can signal possible liver injury. An abnormal result needs medical evaluation. The hepatitis C trial did not establish an ALT benefit for its tested silymarin regimens.

Before the test if you already supplement

For a planned liver panel, tell the clinician about milk thistle, the dose and the last dose. MedlinePlus’s liver-test guidance^[14] says fasting and medicine changes depend on the tests ordered; it gives no milk-thistle stop interval. Ask how to handle the supplement before collection.

The bottom line

Milk thistle’s long association with the liver has not turned into a dependable liver-treatment benefit. The hepatitis C trial did not establish benefit. Fatty-liver studies have mixed findings: one US trial was inconclusive, while another found a secondary fibrosis signal despite missing its main target. Older cirrhosis trials disagree. Small diabetes and antioxidant studies offer some positive measurements alongside a newer null diabetes trial; they do not establish liver repair.

If you choose a product, identify the silymarin amount—or the silybin content of a phospholipid complex—rather than counting seed powder or the whole complex as the same thing. More importantly, a “liver support” bottle should not replace finding the cause of abnormal liver results or following an established treatment. The marketing is more certain than the evidence.

Help us improve this article

Spotted an error or found a source we should consider? Tell us which part of this article needs another look and include a link if you have one. Please leave out personal health details and lab results; we can’t answer individual medical questions.

Your name

Email address

What would you like to share?Select a topicCorrectionSource or research suggestionArticle requestAccessibility issueBusiness inquirySomething else

Your message

Continue to email →Email us directly